Corbus Pharmaceuticals Holdings, Inc.
CRBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595097
In the last 90 days, Corbus Pharmaceuticals Holdings, Inc. insiders filed 1 open-market purchase and 3 sales; 107 institutions reported holding it in 13F filings for Q2 2026, worth $129.5M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $25.0K in total
- 1
- Insider sellsLast 90 days, $308.0K in total
- 3
- 13F holdersQ2 2026, +1 vs. previous quarter
- 107
- 13F valueReported value at the end of Q2 2026
- $129.5M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CRBP, Q2 2026
No superinvestor reported holding CRBP at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Corbus Pharmaceuticals Holdings, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 (view filing)4:59 PM ET | Sep 14 | 1 day | Ben YongDirector | SSaleCommon Stock, par value $0.0001 per share | −2.00K | $7.84 | −$15.7K | −17.6%9.38K after | 10b5-1 |
| Aug 12, 2026 (view filing)4:30 PM ET | Aug 11 | 1 day | Saxena Nishant CChief Business Officer | PPurchaseCommon Stock, par value $0.0001 per share | +2.60K | $9.63 | +$25.0K | +3.5%77.9K after | |
| Aug 10, 2026 (view filing)4:30 PM ET | Aug 7 | 3 days | Cohen YuvalChief Executive Officer | SSaleCommon Stock, par value $0.0001 per share | −17.0K | $10.08 | −$171.4K | −9.8%157.3K after | 10b5-1 |
| Aug 10, 2026 (view filing)4:30 PM ET | Aug 7 | 3 days | Moran Sean F.Chief Financial Officer | SSaleCommon Stock, par value $0.0001 per share | −12.0K | $10.08 | −$121.0K | −12.4%84.7K after | 10b5-1 |
| Jun 11, 2026 (view filing) | Jun 10 | 1 day | Kung WinstonDirector | SSaleCommon Stock, par value $0.0001 per share | −2.03K | $7.91 | −$16.0K | −14.3%12.1K after | 10b5-1 |
| Jun 11, 2026 (view filing) | Jun 10 | 1 day | Jenkins John KennethDirector | SSaleCommon Stock, par value $0.0001 per share | −4.80K | $7.91 | −$38.0K | −55.6%3.83K after | 10b5-1 |
| Jun 11, 2026 (view filing) | Jun 10 | 1 day | Altmeyer AnneDirector | SSaleCommon Stock, par value $0.0001 per share | −2.41K | $7.91 | −$19.1K | −24.1%7.58K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 2-3 | 1 day | Saxena Nishant CChief Business Officer | PPurchaseCommon Stock, par value $0.0001 per share | +13.5K | $7.50 | +$101.2K | +21.8%75.3K after | 2 lots |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Smethurst DominicChief Medical Officer | SSaleCommon Stock, par value $0.0001 per share | −6.10K | $8.30 | −$50.6K | −6.4%89.8K after | |
| Feb 18, 2026 (view filing) | Feb 17 | 1 day | Hodgson IanChief Operating Officer | SSaleCommon Stock, par value $0.0001 per share | −847 | $7.38 | −$6.25K | −1.6%51.1K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Corbus Pharmaceuticals Holdings, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 2,344,971 | $22.0M | 1.13% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 1,737,287 | $16.3M | 0.31% | 00.0% | Unchanged |
| BlackRock, Inc. | 1,331,135 | $12.5M | 0.00% | +1,059,499+390.0% | Added |
| Standard Life Aberdeen plc | 1,321,750 | $12.4M | 0.02% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 760,940 | $7.14M | 0.00% | +26,834+3.7% | Added |
| Jones Hill Capital LP | 653,572 | $6.13M | 1.30% | +653,572 | New |
| Prosight Management, LP | 650,000 | $6.10M | 1.05% | −47,108−6.8% | Reduced |
| Stonepine Capital Management, LLC | 425,000 | $3.99M | 3.03% | +41,538+10.8% | Added |
| Geode Capital Management, LLC | 423,374 | $3.97M | 0.00% | +236,345+126.4% | Added |
| ADAR1 Capital Management, LLC | 421,787 | $3.96M | 0.19% | +90,006+27.1% | Added |